- Home
- VCIG vs AYTU Comparison
VCIG vs AYTU Comparison
Compare VCIG & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VCIG
- AYTU
- Stock Information
- Founded
- VCIG 2013
- AYTU N/A
- Country
- VCIG Malaysia
- AYTU United States
- Employees
- VCIG N/A
- AYTU N/A
- Industry
- VCIG Diversified Commercial Services
- AYTU Biotechnology: Pharmaceutical Preparations
- Sector
- VCIG Consumer Discretionary
- AYTU Health Care
- Exchange
- VCIG Nasdaq
- AYTU Nasdaq
- Market Cap
- VCIG 22.5M
- AYTU 19.7M
- IPO Year
- VCIG 2023
- AYTU N/A
- Fundamental
- Price
- VCIG $0.72
- AYTU $2.26
- Analyst Decision
- VCIG
- AYTU Strong Buy
- Analyst Count
- VCIG 0
- AYTU 2
- Target Price
- VCIG N/A
- AYTU $10.00
- AVG Volume (30 Days)
- VCIG 7.6M
- AYTU 79.7K
- Earning Date
- VCIG 11-19-2025
- AYTU 09-25-2025
- Dividend Yield
- VCIG N/A
- AYTU N/A
- EPS Growth
- VCIG N/A
- AYTU N/A
- EPS
- VCIG 54.73
- AYTU N/A
- Revenue
- VCIG $27,819,290.00
- AYTU $81,659,000.00
- Revenue This Year
- VCIG N/A
- AYTU N/A
- Revenue Next Year
- VCIG N/A
- AYTU $2.00
- P/E Ratio
- VCIG $0.01
- AYTU $12.32
- Revenue Growth
- VCIG 36.99
- AYTU 0.41
- 52 Week Low
- VCIG $0.66
- AYTU $0.95
- 52 Week High
- VCIG $176.40
- AYTU $2.85
- Technical
- Relative Strength Index (RSI)
- VCIG 38.36
- AYTU 46.67
- Support Level
- VCIG $0.74
- AYTU $2.25
- Resistance Level
- VCIG $0.79
- AYTU $2.39
- Average True Range (ATR)
- VCIG 0.10
- AYTU 0.12
- MACD
- VCIG 0.02
- AYTU 0.00
- Stochastic Oscillator
- VCIG 12.66
- AYTU 46.88
About VCIG VCI Global Limited
VCI Global Ltd is a holding company. The principal activities of the Company and its subsidiaries are the provision of business Strategy consultancy and technology development. The firm organized its consulting services into three main segments: Business Strategy Consultancy; Technology development, solutions and consultancy; and Others. It derives the majority of its revenue from the Business Strategy Consultancy segment, which focuses on listing solutions, investor relations, and boardroom strategies consultancy.
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.